Skip to Main Content

Paper Details

Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
Nat Med
1
2022
Stem cell, myelodysplastic syndrome, venetoclax
Author NameAffiliation
Ganiraju C ManyamThe University of Texas MD Anderson Cancer Center
Rashmi Kanagal-ShamannaThe University of Texas MD Anderson Cancer Center
Michael D McLellanMcDonnell Genome Institute, Washington University in St. Louis
Michael D McLellanMcDonnell Genome Institute, Washington University in St. Louis
Matteo PellegriniMolecular Biology Institute, University of California los angeles
Jason WalkerMcDonnell Genome Institute, Washington University in St. Louis
Guillermo Garcia-ManeroThe University of Texas MD Anderson Cancer Center
  • 1 - 7

Datasets

Release 1.2